Chewed Versus Swallowed Ticagrelor in P2Y12 Inhibitor-Naïve Patients Undergoing Percutaneous Coronary Intervention
Journal of Patient-Centered Research and Reviews · 18.04.2023 · 10 (2) · 50-57
DOI: 10.17294/2330-0698.2009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Patient-Centered Research and Reviews, online erschienen am 18.04.2023. Verfasst von Thomas F Wilson und 10 weiteren Autor:innen. Beteiligte Einrichtung: Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St. Luke's Medical Centers, Aurora Health Care, Milwaukee, WI. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Purpose
Dual antiplatelet therapy is standard for patients undergoing percutaneous coronary intervention (PCI) with stents. Traditionally, patients swallow the loading dose of a P2Y12 inhibitor before or during PCI. Time to achieve adequate platelet inhibition after swallowing the loading dose varies significantly. Chewed tablets may allow more rapid inhibition of platelet aggregation. However, data for this strategy in patients with stable ischemic heart disease or non-ST-elevation acute coronary syndrome (NSTE-ACS) are less robust.
Methods
In this single-center prospective trial, 112 P2Y12-naïve patients with stable ischemic heart disease or NSTE-ACS on aspirin therapy and who received ticagrelor after coronary angiography but before PCI were randomized to chewing (n = 55) or swallowing (n = 57) the ticagrelor loading dose (180 mg). Baseline variables were compared using 2-sample t-test and chi-squared/Fisher’s exact tests as appropriate, with alpha set at 0.05. P2Y12 reaction units (PRU) were compared at baseline, 1 hour, and 4 hours using Wilcoxon rank-sum test. Patients then received standard ticagrelor dosing.
Results
After exclusions, P2Y12 PRU in the chewed and swallowed groups at baseline, 1 hour, and 4 hours after ticagrelor loading dose were 243 vs 256 (P = 0.75), 143 vs 210 (P = 0.09), and 28 vs 25 (P = 0.89), respectively. No differences were found in major adverse cardiac events (MACE) or major bleeding at 30 days and 1 year.
Conclusions
In patients with stable ischemic heart disease or NSTE-ACS, chewing rather than swallowing ticagrelor may lead to slightly faster inhibition of platelet aggregation at 1 hour with no increase in MACE or major bleeding.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St. Luke's Medical Centers, Aurora Health Care, Milwaukee, WI.
- Department of Cardiovascular Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Zitieren
APA
Wilson, T. F., Ashraf, M., Jan, M. F., Nfor, T., Kostopoulos, L., Solis, J., Khitha, J., Khraisat, A., DeFranco, A. C., Bajwa, T., & Allaqaband, S. Q. (2023). Chewed Versus Swallowed Ticagrelor in P2Y12 Inhibitor-Naïve Patients Undergoing Percutaneous Coronary Intervention. Journal of Patient-Centered Research and Reviews, 10(2), 50-57. https://doi.org/10.17294/2330-0698.2009
Vancouver
Wilson TF, Ashraf M, Jan MF, Nfor T, Kostopoulos L, Solis J, et al. Chewed Versus Swallowed Ticagrelor in P2Y12 Inhibitor-Naïve Patients Undergoing Percutaneous Coronary Intervention. Journal of Patient-Centered Research and Reviews. 2023;10(2):50-57. doi:10.17294/2330-0698.2009
BibTeX
@article{Wilson2023,
author = {Wilson, Thomas F and Ashraf, Muddasir and Jan, M Fuad and Nfor, Tonga and Kostopoulos, Louie and Solis, Joaquin and Khitha, Jayant and Khraisat, Ahmad and DeFranco, Anthony C and Bajwa, Tanvir and Allaqaband, Suhail Q},
title = {Chewed Versus Swallowed Ticagrelor in P2Y12 Inhibitor-Naïve Patients Undergoing Percutaneous Coronary Intervention},
journal = {Journal of Patient-Centered Research and Reviews},
year = {2023},
volume = {10},
number = {2},
pages = {50--57},
doi = {10.17294/2330-0698.2009}
}
EUVIMED